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Comparison of serum levels of IL-6, IL-8, TNF-α, C reactive
protein and heat shock protein 70 in patients with active or
inactive Behçet’s disease
Remzi KARADAĞ1, Cemile KOCA2, Yüksel TOTAN1, Ramazan YAĞCI1, Murat AYDIN2,
Ayşe Serap KARADAĞ3, Gülfer AKBAY4, Meral EKŞİOĞLU4, Ramazan YİĞİTOĞLU2

Aim: The aim of this study was to elucidate serum levels of IL-6, IL-8, TNF-α, CRP, and HSP 70 in patients with active
or inactive Behçet’s disease.
Materials and methods: The study included 50 patients who met the International Study Group criteria for Behçet’s
disease. Of these, 26 had active disease and 24 had inactive disease. The control group was comprised of 25 age- and sexmatched healthy participants. Serum levels of IL-6, IL-8, TNF-α, CRP, and HSP 70 were measured.
Results: In patients with active disease, significantly higher mean serum levels of IL-6, IL-8, TNF-α, and CRP were found
compared to patients with inactive disease or in controls (overall, P < 0.05). In patients with active disease, the mean
serum level of HSP 70 was significantly higher than that of the control group (P = 0.02). In patients with inactive disease
it was higher compared to the controls but with a significance level close to 0.05 (P = 0.044). However, HSP 70 levels did
not differ significantly between patients with active disease and patients with inactive disease (P = 0.93).
Conclusion: The results of our study suggest that serum IL-6, IL-8, TNF-α, and CRP levels are increased in patients with
active Behçet’s disease. HSP 70 levels in both active and inactive disease groups were higher than in controls, though it
was significant only in the active group. This suggests that HSP 70 has a role in the chronic nature of Behçet’s disease,
with HSP 70 expression possibly not falling to normal levels in the inactive phase of the disease.
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Aktif ve inaktif Behçet hastalarında serum İL-6, İL-8, TNF- α, C reaktif protein ve ısı
şok protein 70 düzeylerinin karşılaştırılması
Amaç: Bu çalışmanın amacı, aktif ve inaktif Behçet hastalarında serum İL-6, İL-8, TNF-α, CRP ve HSP 70 düzeylerini
araştırmaktır.
Yöntem ve gereç: Çalışmaya Uluslararası Çalışma Grubunu kriterlerine gore Behçet hastalığı tanısı almış 50 hasta alındı.
Bunların 26’sı aktif ve 24’ü inaktif hastalığa sahipti. Kontrol grubu yaş ve cinsiyet olarak çalışma grubuna benzeyen 25
sağlıklı bireyden oluşmaktaydı. Serum İL-6, İL-8, TNF-α, CRP ve HSP 70 düzeyleri ölçüldü.
Bulgular: Ortalama serum İL-6, İL-8, TNF-α ve CRP düzeyleri aktif hastalığı olanlarda, inaktif hastalığı olanlar ve kontrol
grubuna göre anlamlı şekilde yüksek bulundu ( hepsinde, P < 0,05). Ortalama serum HSP 70 düzeyi aktif hastalığı
olanlarda kontrol grubuna göre anlamlı şekilde yüksek iken (P = 0,02), inaktif hastalığı olanlarda kontrol grubuna göre
sınırda anlamlı yüksek bulundu (P = 0,044). Bununla birlikte aktif ve inaktif hastalar arasında anlamlı fark tespit edilmedi
(P = 0,93).
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Sonuç: Aktif Behçet hastalarında serum serum İL-6, İL-8, TNF-α ve CRP düzeyleri artmaktadır. HSP 70 düzeyi aktif
hastalarda belirgin olmak üzere hem aktif hem de inaktif hasta grubunda kontrol grubuna göre yüksek bulunmaktadır.
Bu da, HSP 70’in Behçet hastalığının kronik seyrinde rol aldığını ve inaktif hastalık fazında HSP 70 düzeyleri normal
değerlerine kadar yeterince düşmediğini göstermektedir.
Anahtar sözcükler: Behçet hastalığı, kemokin, C-reaktif protein, sitokin, ısı şok protein, interlökin

Introduction
Behçet’s disease is a recurring inflammatory
disorder characterized by 4 major findings: oral
aphthous ulcers, ocular lesions, skin lesions, and
genital ulcerations, with inflammation also
occasionally occurring in other tissues and organs,
such as the cardiovascular system, central nervous
system, gastrointestinal tract, lungs, kidneys, and
joints (1). The causal mechanism of Behçet’s disease
has not been determined, but genetic, infectious, and
immune mechanisms have been proposed (1).
A role for autoimmunity in Behçet’s disease is
suggested
by
reports
of
increases
in
immunoglobulins, immune complexes, and
complement and acute phase proteins (2,3). Given the
immune activation that occurs in Behçet’s disease, the
course of the disease might also be influenced by proinflammatory cytokines (4,5). These proteins are
produced by various cell types and are important
mediators of immune and inflammatory responses
(6).
Another class of proteins important in infection
and immunity, and possibly in Behçet’s disease, is that
of the heat shock proteins, which are a group of
proteins that are common to many organisms, they
range in molecular weight from 8 kDa to 150 kDa,
and are rapidly produced by most cells in response to
environmental stresses (7,8). Heat shock proteins are
capable of eliciting immune responses (9), have been
proposed as a source of cross-reactivity that could link
infection and autoimmunity (10), and may play a role
in regulating immune response pathways (8). Among
the heat shock proteins, heat shock protein 70 (HSP
70) has been reported to have both pro-inflammatory
(11,12) and anti-inflammatory (13-17) properties. In
its pro-inflammatory role, HSP 70 appears to bind
with receptors on antigen presenting cells and to
stimulate cytokine secretion (12), as well as facilitating
antigen presentation (18). In its anti-inflammatory
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role, HSP 70 decreases the release of inflammatory
mediators (15-17). The administration of
recombinant HSP 70 has been reported to attenuate
the experimental autoimmune disease (19). Heat
shock proteins appear to be involved in the etiology of
Behçet’s disease, but the details of this involvement are
not yet clear (7,11).
Behçet’s disease is generally diagnosed based on
the clinical criteria established by the International
Study Group for Behçet’s disease (20). To date,
increased serum levels of biochemical parameters,
such as cytokines (3-5), lipoprotein A (21), and C
reactive protein (CRP) (22) have been proposed as
disease activity markers; however, no single parameter
has been widely accepted as an indicator of disease
activity.
Given the intricate involvement of cytokines and
heat shock proteins in inflammation and possibly in
Behçet’s disease, as well as the lack of a marker for
activity in this disease, the aim of the present study
was to investigate serum levels of cytokines, CRP, and
HSP 70 in patients with active or inactive Behçet’s
disease.
Materials and methods
This cross-sectional study included 50 patients
who met the International Study Group criteria for
Behçet’s disease (20) (13 male, 37 female, mean age
34.8 ± 8.8 years). Of these, 26 had active disease and
24 had inactive disease. Age- and sex-matched 25
healthy participants (7 male, 18 female, mean age 34.1
± 6.0 years) were enrolled in the study as controls.
Active Behçet’s disease was defined as the presence
of at least 2 of the characteristic findings according to
the Behçet’s Disease Current Activity Form (23).
Patients who had been free of lesions for the previous
30 days or more were regarded as having inactive
disease. According to these criteria, 26 patients had
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active disease (19 female, 7 male, mean age 35.5 ± 8.3
years) and 24 had inactive disease (18 female, 6 male,
mean age 34.0 ± 9.5 years). Patients with acute
infection or any inflammatory disease other than
Behçet’s disease and who were on medications that
may affect serum levels of cytokines, HSP-70, and
CRP were not included in the study.
Venous blood samples were taken from the
antecubital vein for biochemical assays. The blood
samples were centrifuged at 1000 ×g for 15 min at 4 °C
to separate the serum. Serum samples were
immediately stored at −80 °C until analysis. Serum
levels of CRP were determined using a nephelometer
(Immage, Beckman Coulter, CA, USA). For the other
parameters, serum levels were determined with
enzyme-linked immunoassay kits as follows: IL-6
(Biosource International, CA, USA), IL-8 (Orgenium,
Finland), TNF-α (Biosource International, CA, USA),
and HSP 70 (Stressgen, Canada). IL-6, IL-8, and TNFα were expressed as pg/mL, HSP 70 was expressed as
ng/mL, and CRP was expressed as mg/mL.
Statistical analyses were performed with SPSS 10.0
(SPSS Inc., Chicago, IL, USA). Results were expressed
as mean ± standard deviation. The data were normally
distributed. Analysis of variance (ANOVA) and
Tukey’s Honestly Significant Differences test were
used to compare the means of the 3 groups;
significance was defined as P < 0.05.

Results
Clinical characteristics and laboratory findings for
patients with active or inactive disease are
summarized in Table 1.
In patients with inactive disease, serum levels of
all biochemical parameters measured were similar to
those in the control group, and no significant
differences were found between these groups. In
patients with active disease, serum levels of IL-6, IL8, TNF-α, and CRP were significantly higher
compared to either the inactive disease group or the
control group.
In patients with inactive disease, the mean serum
HSP 70 concentration was just at the level of
significance, being higher than in the control group.
In patients with active disease, the mean HSP 70
concentration was significantly higher compared to
the controls (P = 0.02); however, between patients
with active disease and those with inactive disease, the
difference in HSP 70 was not significant (P = 0.93).
Discussion
Behçet’s disease is a chronic inflammatory
disorder that can involve multiple organ systems, and
is characterized by exacerbations and remissions
whose mechanisms are still unclear (1,7,11).
Inflammatory mediators have been investigated in

Table 1. HSP 70 and inflammatory mediator levels in patients with active or inactive Behçet’s disease.

Age *
Gender (F/M)
¥

CRP ± SD

HSP 70 ± SD
IL-8 ± SD

¥

IL-6 ± SD

¥

TNF-α ± SD

¥

¥

£

Control (n = 25)

Inactive (n = 24)

Active (n = 26)

p (C-I)

p (I-A)

p (C-A)

34.1 ± 6.0

34.0 ± 9.5

35.5 ± 8.3

0.53

18/7

18/6

19/7

0.97

0.29 ± 0.29

0.32 ± 0.20

0.49 ± 0.28

0.68

0.04

0.03

622.11 ± 244.20

871.92 ± 560.48

909.44 ± 251.92

0.044

0.93

0.02

14.48 ± 5.15

20.26 ± 8.55

27.41 ± 12.95

0.107

0.035

<0.001

13.36 ± 0.51

14.34 ± 1.79

15.68 ± 1.99

0.077

0.008

<0.001

8.67 ± 2.01

10.56 ± 3.21

13.18 ± 4.38

0.162

0.032

<0.001

Abbreviations: C: Control group, I: Inactive disease group, A: Active disease group, F: Female, M: Male
* Student’s t test,
£
Mann-Whitney U test,
¥
ANOVA test used.
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patients with Behçet’s disease, and some of these
mediators appear to be associated with the clinical
activity of the disease (24).
IL-6 is a glycoprotein secreted mainly by activated
monocytes and macrophages, but it is also produced
by many other cell types. It influences antigen-specific
immune responses and inflammatory reactions, and
has been found to be abnormally increased in some
autoimmune diseases and chronic inflammatory
reactions (25). IL-6 has been found increased in some
studies in the serum of patients with Behçet’s disease
(3-5) ; however, other studies have found similar
serum IL-6 levels in patients with active Behçet’s
disease and patients with inactive Behçet’s disease,
(26) and in patients with active Behçet’s disease and
healthy control subjects (6). Among our patients,
serum IL-6 levels were significantly higher in those
with active compared to those with inactive disease,
which suggests that IL-6 is involved in the mechanism
that determines the activity of the disease.
IL-8 is a cytokine that attracts and activates
leukocytes in addition to attracting T cells and
basophils. IL-8 is also involved in the conversion of
mononuclear to granulocytic infiltration and in the
enhanced adhesion of peripheral blood leukocytes to
endothelial cells. IL-8 is mainly produced by
monocytes/macrophages, T cells, granulocytes, and
endothelial cells, but can also be produced by
fibroblasts, keratinocytes, hepatocytes, and
chondrocytes (27). In patients with Behçet’s disease,
some studies have found IL-8 levels to be higher in
the active phase of the disease (3,4) while others have
found it to be unchanged (28). This difference in
findings may be due to the fact that different criteria
for active disease were used in some studies. Our
finding that IL-8 levels were significantly higher in
patients with active versus inactive disease is
consistent with the role of IL-8 in the inflammatory
response and its attraction of polymorphonuclear cells
into lesions, which is seen in Behçet’s disease.
TNF-α is a cytokine secreted by lymphocytes and
reticuloendothelial cells, and its serum levels are
increased in many acute and chronic inflammatory
diseases (29). As with the other cytokines, some
previous studies involved patients with Behçet’s
disease have found TNF-α levels to be increased in the
active phase relative to the inactive phase of the
60

disease, (3,23) while other studies have found no
difference (6,27). We found TNF-α levels to be higher
in patients with active disease. CRP levels were also
higher in our patients with active disease relative to
those with inactive disease, as would be expected
given the increases in CRP that are generally seen in
acute diseases.
Heat shock proteins, especially HSP 60/65, have
been implicated in the etiology of Behçet’s disease, for
example as antigens providing for cross-reactivity
against infectious agents and host tissues (11).
However, specific roles of different heat shock
proteins in Behçet’s disease are unclear. For example,
antibodies against HSP 70 were found in patients with
Behçet’s disease, but serum levels of these antibodies
were not correlated with serum HSP 70 levels (30).
This raises the question of whether the occurrence of
HSP 70 in the course of Behçet’s disease might be a
reaction against the pathogenesis rather than a
contributor to it.
The possibility that HSP 70 expression is an antiinflammatory response is supported by several
studies. In a study of experimental autoimmune
uveoretinitis in mice, Kitamei et al. (13) found that
induction of HSP 70 expression reduced the
histopathological severity of the disease. In humans
taking Diclofenac, Yanaka et al. (14) administered the
drug geranylgeranylacetone to induce HSP
expression, and observed a reduction in the damage
to gastric mucosa caused by the former drug. In
experimental stroke in mice overexpressing HSP 70,
Zheng et al. (15) found that the inflammatory
transcription factor nuclear factor kB was inhibited.
In vitro studies also appear to attribute an antiinflammatory role for HSP 70. In enterocyte-like cells,
Malago et al. (16) used Salmonella to induce IL-8
expression, and concluded that IL-8 down-regulation
might be in part mediated by the production of HSP
70. In fibroblast-like synoviocytes, Luo et al. (17) used
TNF-α to induce production of IL-6, IL-8, and
monocyte chemoattractant protein-1 and found that
HSP 70 could downregulate these cytokines.
In conclusion, we found that IL-6, IL-8, TNF-α,
and CRP levels were significantly higher in patients
with active Behçet’s disease than in those with inactive
disease. These molecules might therefore be useful in
monitoring the effect of therapy in patients with
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Behçet’s disease. HSP 70 levels in both active and
inactive disease groups were higher than in controls,
though it was significant only in the active group,
which suggests that HSP 70 has a role in the chronic
nature of Behçet’s disease, with HSP 70 expression in

the inactive phase possibly remaining slightly higher
than the baseline levels before the original onset of the
disease. Further studies are warranted to elucidate the
role of these parameters on management and
prognosis of Behçet’s disease.
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